Merck's Victrelis is NICEr than peginterferon alfa and ribavirin
This article was originally published in Scrip
Merck & Co's hepatitis C drug, Victrelis (boceprevir) offers a "major benefit" for hepatitis C patients, compared to current treatment with peginterferon alfa and ribavirin alone, says NICE, the health technology appraisal institute for England and Wales. The institute has fast-tracked the appraisal process and issued final draft guidance recommending the drug without first issuing preliminary draft recommendations.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.